Literature DB >> 21684355

Atherosclerosis in psoriatic arthritis.

R Ramonda1, A Lo Nigro, V Modesti, L Nalotto, E Musacchio, L Iaccarino, L Punzi, A Doria.   

Abstract

The atherosclerotic process is accelerated in several autoimmune rheumatic diseases. Effector cells of innate and adaptive immunity along with pro-inflammatory cytokines and other immune mediators are found in atherosclerotic lesions, where they play an important role in induction, progression and rupture of plaques. Psoriatic arthritis (PsA) is a chronic inflammatory disease, characterized by arthritis, enthesitis, dactilytis, osteitis, and axial involvement, along with skin manifestations. PsA is frequently associated with obesity, diabetes, dyslipidemia, hypertension, accelerated atherosclerosis and with increased cardiovascular morbidity and mortality. Disease-specific and traditional risk factors seem to account for the atherosclerotic burden in PsA patients. Some immunological factors which are involved in PsA can also contribute to atherosclerosis including C reactive protein (CRP), TNF-α, IFN-γ, IL-1, Il 6, IL23, and Th17.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21684355     DOI: 10.1016/j.autrev.2011.05.022

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  17 in total

1.  Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study.

Authors:  Luisa Costa; Francesco Caso; Roberta Ramonda; Antonio Del Puente; Luca Cantarini; Md Abud Darda; Paolo Caso; Mariagrazia Lorenzin; Ugo Fiocco; Leonardo Punzi; Raffaele Scarpa
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

2.  [Diagnosis and therapy of early psoriatic arthritis].

Authors:  M Köhm; F Behrens
Journal:  Z Rheumatol       Date:  2012-01       Impact factor: 1.372

3.  Transient receptor potential melastatin 2: a novel target for treatment of gout.

Authors:  Zhenyu Zhong; Yougang Zhai; Liang Qiao
Journal:  Expert Opin Ther Targets       Date:  2013-09-04       Impact factor: 6.902

4.  Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients.

Authors:  Luisa Costa; Francesco Caso; Mariangela Atteno; Antonio Del Puente; Md Abud Darda; Paolo Caso; Augusta Ortolan; Ugo Fiocco; Roberta Ramonda; Leonardo Punzi; Raffaele Scarpa
Journal:  Clin Rheumatol       Date:  2014-06       Impact factor: 2.980

Review 5.  Making the next steps in psoriatic arthritis management: current status and future directions.

Authors:  Diviya Sritheran; Ying Ying Leung
Journal:  Ther Adv Musculoskelet Dis       Date:  2015-10       Impact factor: 5.346

6.  Impact of hypertension on vascular remodeling in patients with psoriatic arthritis.

Authors:  M Puato; R Ramonda; A Doria; M Rattazzi; E Faggin; G Balbi; M Zanon; M Zanardo; C Tirrito; M Lorenzin; V Modesti; M Plebani; M Zaninotto; L Punzi; P Pauletto
Journal:  J Hum Hypertens       Date:  2013-07-11       Impact factor: 3.012

7.  Cardiovascular risk in patients with psoriatic arthritis.

Authors:  Tracy Y Zhu; Edmund K Li; Lai-Shan Tam
Journal:  Int J Rheumatol       Date:  2012-05-08

Review 8.  The Th17 axis in psoriatic disease: pathogenetic and therapeutic implications.

Authors:  Beatrice Marinoni; Angela Ceribelli; Marco S Massarotti; Carlo Selmi
Journal:  Auto Immun Highlights       Date:  2014-01-22

Review 9.  Asymmetric dimethylarginine as a surrogate marker of endothelial dysfunction and cardiovascular risk in patients with systemic rheumatic diseases.

Authors:  Theodoros Dimitroulas; Aamer Sandoo; George D Kitas
Journal:  Int J Mol Sci       Date:  2012-09-26       Impact factor: 5.923

Review 10.  Association Between Psoriasis and Subclinical Atherosclerosis: A Meta-Analysis.

Authors:  Na Fang; Menglin Jiang; Yu Fan
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.